Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2024 | Asciminib versus other TKIs in the frontline treatment of CML: the ASC4FIRST study

Jorge Cortes • 1 Jun 2024
ASCO 2024
Chronic Myeloid Leukemia Leukemia Asciminib Imatinib
ASC4FIRST

Jorge Cortes, MD, Georgia Cancer Center, Augusta University, Augusta, GA, discusses the ASC4FIRST study (NCT04971226), comparing asciminib to imatinib and other second-generation tyrosine kinase inhibitors (TKIs) in the frontline treatment of chronic myeloid leukemia (CML). There was a significant benefit in the rate of major molecular response (MMR) at 48 weeks in those treated with asciminib, as well as an improved safety profile. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Jorge Cortes

Dynamically adjusting the dose and dosing schedule of TKIs in patients with CML 2:09
Dynamically adjusting the dose and dosing schedule of TKIs in patients with CML
Jorge Cortes • 4 Sep 2025
Aiming to further improve the outcomes of patients with CML 1:39
Aiming to further improve the outcomes of patients with CML
Jorge Cortes • 4 Sep 2025
Efficacy and safety of olutasidenib monotherapy in relapsed/refractory AML 1:49
Efficacy and safety of olutasidenib monotherapy in relapsed/refractory AML
Jorge Cortes • 4 Sep 2025
Unmet needs and treatment goals in CML: insights from a patient and physician survey 2:23
Unmet needs and treatment goals in CML: insights from a patient and physician survey
Jorge Cortes • 4 Sep 2025

Related Videos

The value and mission of the International Workshop on Acute Leukemias 14:36
The value and mission of the International Workshop on Acute Leukemias
Charles Craddock et al. • 21 Oct 2025
One big question with Koichi Takahashi: what AML advance could transform frontline care in 3 years? 1:30
One big question with Koichi Takahashi: what AML advance could transform frontline care in 3 years?
Koichi Takahashi • 26 Sep 2025
One big question with Naval Daver: what AML advance could transform frontline care in three years? 1:05
One big question with Naval Daver: what AML advance could transform frontline care in three years?
Naval Daver • 26 Sep 2025
One big question with Charles Craddock: what AML advance could transform frontline care in 3 years? 3:13
One big question with Charles Craddock: what AML advance could transform frontline care in 3 years?
Charles Craddock • 26 Sep 2025
The content of VJHemOnc is intended for healthcare professionals